New combo therapy for smokers with schizophrenia: early hints, big questions

NCT ID NCT06374290

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 33 times

Summary

This small pilot study tested whether a combination of an injectable drug (naltrexone) and an oral drug (bupropion) is safe and feasible for helping people with schizophrenia quit smoking. Only 2 participants were enrolled before the study was terminated. The goal was to see if the treatment could reduce cigarette cravings and smoking without worsening schizophrenia symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • The University of Texas health Science Center at Houston

    Houston, Texas, 77030, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Naltrexone (extended-release injection) and bupropion (oral tablet)

What this could lead to

If it works, this could point toward a safe way to help people with schizophrenia quit smoking.

What could go wrong

This is a very early, tiny pilot study (only 2 participants) that was terminated. Results may not apply to larger groups, and side effects are not well understood.

Conditions

The condition(s) this trial relates to.

schizophrenia Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.